+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Tolerability and Efficacy of Antihypertensive Treatment with Cilazapril in General Practice

      a , b
      S. Karger AG
      Angiotensin-converting enzyme inhibitor, Cilazapril, Tolerability, Hypertension

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Data on the safety, tolerability and efficacy of the new angiotensin-converting enzyme (ACE) inhibitor cilazapril were obtained in a multicenter observational study carried out in a general practice setting. A total of 33,841 hypertensive patients were prescribed cilazapril 2.5-5.0 mg per day and followed for an average of 109 days. 28,792 patients (85.1%) had a baseline diastolic blood pressure (BP) ≧ 95 mm Hg. 24,649 patients received cilazapril alone. During the observation period the mean blood pressure of these patients fell from 177/105 to 148/87 mm Hg (an average drop Δ of 29/18 mm Hg). The response rate (diastolic BP ≤ 90 mm Hg and A ≧ 10 mm Hg) in these patients was 78.9%. Adverse events were reported by 7.3% of all patients. In all, 3.7% of patients discontinued cilazapril treatment because of side effects. The most frequently reported side effect (1.5% of cases) was the dry cough typical of ACE inhibitors. The doctors judged the efficacy of cilazapril as very good or good in 89.8% of cases and its tolerability as very good or good in 94.6%. This reflects the good compliance (regular tablet intake) of more than 90% of patients.

          Related collections

          Author and article information

          S. Karger AG
          19 November 2008
          : 87
          : 1
          : 54-59
          aDepartment of Pharmacotherapy, University of Ulm, and bE. Merck, Darmstadt, Germany
          177060 Cardiology 1996;87:54–59
          © 1996 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          : 26 July 1995
          : 27 July 1995
          Page count
          Pages: 6
          Clinical Pharmacology

          General medicine,Neurology,Cardiovascular Medicine,Internal medicine,Nephrology
          Tolerability,Cilazapril,Hypertension,Angiotensin-converting enzyme inhibitor


          Comment on this article